Braun Stacey Associates Inc. acquired a new stake in Guardian Pharmacy Services, Inc. (NYSE:GRDN - Free Report) in the 2nd quarter, according to the company in its most recent filing with the SEC. The firm acquired 339,947 shares of the company's stock, valued at approximately $14,234,000. Braun Stacey Associates Inc. owned about 0.68% of Guardian Pharmacy Services as of its most recent filing with the SEC.
Several other hedge funds have also recently modified their holdings of the company. Boston Partners grew its holdings in shares of Guardian Pharmacy Services by 418.7% in the third quarter. Boston Partners now owns 1,046,877 shares of the company's stock valued at $26,922,000 after acquiring an additional 845,048 shares in the last quarter. Jennison Associates LLC lifted its holdings in Guardian Pharmacy Services by 609.5% during the first quarter. Jennison Associates LLC now owns 822,784 shares of the company's stock worth $30,986,000 after acquiring an additional 706,823 shares during the period. Loomis Sayles & Co. L P bought a new stake in Guardian Pharmacy Services during the fourth quarter worth $19,126,000. Millennium Management LLC boosted its position in Guardian Pharmacy Services by 725.2% in the third quarter. Millennium Management LLC now owns 342,038 shares of the company's stock worth $8,972,000 after purchasing an additional 300,587 shares during the last quarter. Finally, TimesSquare Capital Management LLC boosted its position in Guardian Pharmacy Services by 21.9% in the fourth quarter. TimesSquare Capital Management LLC now owns 1,048,136 shares of the company's stock worth $31,538,000 after purchasing an additional 187,963 shares during the last quarter.
Wall Street Analyst Weigh In
GRDN has been the subject of several research analyst reports. Truist Financial raised their target price on Guardian Pharmacy Services from $43.00 to $47.00 and gave the company a "buy" rating in a research report on Wednesday, June 17th. Weiss Ratings upgraded shares of Guardian Pharmacy Services from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Thursday, August 20th. Wall Street Zen upgraded shares of Guardian Pharmacy Services from a "hold" rating to a "buy" rating in a report on Sunday, August 9th. Zacks Research cut shares of Guardian Pharmacy Services from a "strong-buy" rating to a "hold" rating in a research note on Monday, May 11th. Finally, Oppenheimer raised their price target on shares of Guardian Pharmacy Services from $43.00 to $49.00 and gave the stock an "outperform" rating in a research note on Friday, August 7th. Eight equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $43.83.
Read Our Latest Research Report on GRDN
Guardian Pharmacy Services Stock Down 0.1%
NYSE GRDN opened at $37.29 on Friday. The firm has a market cap of $1.86 billion, a P/E ratio of 36.20, a price-to-earnings-growth ratio of 1.93 and a beta of 0.10. The company's 50 day moving average is $39.89 and its 200-day moving average is $37.88. Guardian Pharmacy Services, Inc. has a 12-month low of $23.14 and a 12-month high of $47.02.
Guardian Pharmacy Services (NYSE:GRDN - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.29 EPS for the quarter, topping the consensus estimate of $0.26 by $0.03. Guardian Pharmacy Services had a net margin of 4.50% and a return on equity of 29.97%. The company had revenue of $351.77 million during the quarter, compared to the consensus estimate of $340.45 million. Equities analysts expect that Guardian Pharmacy Services, Inc. will post 1.19 EPS for the current year.
Guardian Pharmacy Services Profile
(
Free Report)
Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company's Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Guardian Pharmacy Services, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Guardian Pharmacy Services wasn't on the list.
While Guardian Pharmacy Services currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.